Teacher Retirement System of Texas Has $354,000 Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Teacher Retirement System of Texas boosted its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 18.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,532 shares of the company’s stock after buying an additional 1,013 shares during the quarter. Teacher Retirement System of Texas’ holdings in MoonLake Immunotherapeutics were worth $354,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Barclays PLC boosted its stake in shares of MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after acquiring an additional 5,229 shares during the period. PNC Financial Services Group Inc. lifted its holdings in MoonLake Immunotherapeutics by 3.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company’s stock valued at $460,000 after purchasing an additional 320 shares during the last quarter. Erste Asset Management GmbH bought a new position in MoonLake Immunotherapeutics during the third quarter worth $741,000. Y Intercept Hong Kong Ltd increased its holdings in shares of MoonLake Immunotherapeutics by 55.4% in the third quarter. Y Intercept Hong Kong Ltd now owns 20,325 shares of the company’s stock valued at $1,025,000 after purchasing an additional 7,247 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of MoonLake Immunotherapeutics by 96.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,814 shares of the company’s stock valued at $1,806,000 after purchasing an additional 17,580 shares during the period. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Trading Down 2.0 %

Shares of MLTX stock opened at $39.07 on Tuesday. The stock has a 50 day simple moving average of $42.08 and a 200 day simple moving average of $47.70. MoonLake Immunotherapeutics has a 1 year low of $36.52 and a 1 year high of $58.26. The stock has a market cap of $2.50 billion, a P/E ratio of -30.29 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.09). Analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. The Goldman Sachs Group reduced their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Needham & Company LLC upped their target price on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Royal Bank of Canada began coverage on MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They set an “outperform” rating and a $67.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $80.50.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.